Cartalax is a short peptide bioregulator composed of the tripeptide sequence Ala-Glu-Asp (AED), originally developed as part of the peptide bioregulator research programme pioneered by Professor Vladimir Khavinson and colleagues at the St Petersburg Institute of Biogerontology. Peptide bioregulators are short-chain amino acid sequences theorised to interact with specific gene-regulatory mechanisms, potentially influencing the expression of proteins associated with tissue function and repair.
Cartalax has attracted interest in the field of connective tissue and cartilage biology. Preclinical research has investigated its potential influence on chondrocyte activity, extracellular matrix synthesis, and the regulation of genes associated with cartilage homeostasis. It is considered a tissue-specific bioregulator, with preliminary studies suggesting a degree of selectivity for musculoskeletal and cartilaginous tissue.
Cartalax should be stored at -20°C upon receipt, protected from light and moisture. When reconstituted, solutions should be kept at 4°C and used within a short period to maintain stability.
Molecular Formula
C₁₁H₁₇N₃O₈
Molecular Weight
335.3 g/mol
Purity
>98% (HPLC)
CAS Number
460386-73-6
Form
Lyophilised Powder
Research Applications
Cartilage biology, Connective tissue research, Chondrocyte activity, Extracellular matrix synthesis, Musculoskeletal ageing research, Peptide bioregulator studies
For research purposes only. Not for human use.
Reviews
There are no reviews yet.